Literature DB >> 21150242

Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor.

Haitham Tuffaha1, Fawzi Abdel-Latif Abdel-Rahman.   

Abstract

High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation is an important treatment option for a variety of malignancies. Peripheral blood stem cells (PBSCs) have replaced bone marrow-derived cells as source of stem cells in transplants, and the success of a transplant depends highly on the number of PBSCs mobilized, collected and eventually infused. Nevertheless, a good percentage of patients fail to mobilize stem cells when growth factors alone or in combination with chemotherapy are used. Recently, plerixafor has been approved as a novel agent to mobilize stem cells in multiple myeloma and lymphoma patients. Data on the efficacy and safety of plerixafor in solid tumors is lacking. We report the successful stem cell mobilization and transplantation for a patient with a germ cell tumor using plerixafor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150242     DOI: 10.5144/1658-3876.2010.203

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  4 in total

Review 1.  Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

Review 2.  High dose chemotherapy with stem cell support in the treatment of testicular cancer.

Authors:  Lazar Popovic; Gorana Matovina-Brko; Milica Popovic; Dragana Petrovic; Ana Cvetanovic; Jelena Vukojevic; Darjana Jovanovic
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

3.  Successful "on-demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors.

Authors:  Andrea Corbingi; Elisabetta Metafuni; Mariantonietta Di Salvatore; Rossana Putzulu; Patrizia Chiusolo; Giovanni Schinzari; Giuseppina Massini; Ernesto Rossi; Gina Zini; Alessandra Cassano; Simona Sica; Nicola Piccirillo
Journal:  J Clin Apher       Date:  2021-11-25       Impact factor: 2.605

4.  Plerixafor in the treatment of stem cell mobilization failure; first experience in iran.

Authors:  Mahshid Mehdizadeh; Abbas Hajifathali; Mahdi Tabarraee; Maria Tavakoli-Ardakani
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.